Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-DOTA-daratumumab
- Development stage
- Preclinical
- Lead developer
- City of Hope
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
177Lu-DOTA-daratumumab is an experimental radiopharmaceutical composed of the humanized anti-CD38 monoclonal antibody daratumumab conjugated to the beta-emitting radionuclide lutetium-177 (177Lu) via the DOTA chelator. It is designed to treat multiple myeloma by targeting CD38, a surface protein highly expressed on malignant plasma cells. Once bound, the 177Lu isotope emits beta particles that cause lethal DNA damage to the targeted cells. Preclinical research conducted at the City of Hope has compared this beta-emitter conjugate to alpha-emitting alternatives, noting that while 177Lu-DOTA-daratumumab demonstrates antitumor efficacy, its therapeutic potential is constrained by off-target toxicities, particularly bone marrow suppression, due to the relatively long tissue path length of beta radiation.
- Other names
- 177Lu-labeled daratumumabLutetium-177 DOTA-daratumumabLutetium177 DOTA-daratumumabLutetium 177 DOTA-daratumumab
02
Targets
CD38 (Cluster of Differentiation 38)
Beyond the preview
Go deeper on 177Lu-DOTA-daratumumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-DOTA-daratumumab.